Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $73.00 at Chardan Capital

Key Points

• Chardan Capital raised the target price for Palvella Therapeutics from $60.00 to $73.00, indicating a potential upside of 26.54% from its previous close.
• Other analysts have varying target prices, with Oppenheimer setting it at $85.00 and HC Wainwright raising their target to $95.00, reflecting a strong overall consensus on the stock.
• Palvella Therapeutics reported earnings of ($0.86) per share, missing analysts' expectations, with an average target price currently at $67.09.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) had its target price hoisted by investment analysts at Chardan Capital from $60.00 to $73.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Chardan Capital's price objective would indicate a potential upside of 26.54% from the stock's previous close.

Several other research firms also recently commented on PVLA. Oppenheimer started coverage on shares of Palvella Therapeutics in a research report on Tuesday, September 9th. They issued an "outperform" rating and a $85.00 target price for the company. HC Wainwright raised their target price on Palvella Therapeutics from $75.00 to $95.00 and gave the company a "buy" rating in a report on Thursday. Stifel Nicolaus upped their price target on Palvella Therapeutics from $60.00 to $80.00 and gave the stock a "buy" rating in a research note on Wednesday. Lifesci Capital began coverage on Palvella Therapeutics in a report on Monday, August 4th. They issued an "outperform" rating and a $90.00 target price for the company. Finally, Raymond James Financial set a $54.00 price target on shares of Palvella Therapeutics and gave the company an "outperform" rating in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating and eleven have given a Buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $67.09.

Palvella Therapeutics Trading Down 2.0%

Shares of NASDAQ:PVLA opened at $57.69 on Friday. The firm has a market cap of $638.05 million, a price-to-earnings ratio of -4.77 and a beta of -0.03. Palvella Therapeutics has a 1 year low of $11.17 and a 1 year high of $63.12. The business has a fifty day simple moving average of $48.18 and a 200 day simple moving average of $32.63.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, sell-side analysts forecast that Palvella Therapeutics will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PVLA. Police & Firemen s Retirement System of New Jersey acquired a new position in Palvella Therapeutics in the 2nd quarter valued at approximately $37,000. Spire Wealth Management acquired a new stake in shares of Palvella Therapeutics during the 1st quarter worth approximately $70,000. JPMorgan Chase & Co. raised its stake in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock valued at $73,000 after purchasing an additional 3,242 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Palvella Therapeutics in the second quarter worth $85,000. Finally, BNP Paribas Financial Markets acquired a new stake in Palvella Therapeutics during the second quarter worth $104,000. Institutional investors own 40.11% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.